Tonix Pharmaceuticals Holding Corp. has provided an update on their investigational new biologic, TNX-1500, which is designed to address organ transplant rejection and autoimmune disorders. TNX-1500 is a third-generation anti-CD40L monoclonal antibody, re-engineered to enhance Fc receptor modulation while maintaining FcRn function. The company has completed Phase 1 studies and is preparing to initiate Phase 2 studies in kidney transplant recipients. Potential future indications include Sjögren's Syndrome and Systemic Lupus Erythematosus, among others. Collaborations are ongoing with institutions for heart, kidney, and bone marrow transplantation research in non-human primates. TNX-1500 has not yet been approved for any indication. You can access the full presentation through the link below.